Compare IDEXX Laboratories, Inc. (IDXX) vs iShares 10 20 Year Treasury Bond ETF (TLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs iShares 10 20 Year Treasury Bond ETF — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while iShares 10 20 Year Treasury Bond ETF trades at $92.16 (market cap $11.02B). The key difference: IDEXX Laboratories, Inc. is far larger — about 3.7× iShares 10 20 Year Treasury Bond ETF's market cap, and IDEXX Laboratories, Inc. is more actively traded (692,164 versus 6,609,157). Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and iShares 10 20 Year Treasury Bond ETF for 60 Days on average.
| IDXX | TLH | |
|---|---|---|
Market Cap | $40.43B | $11.02B |
Volume | 692,164 | 6,609,157 |
Sector | Health | Fixed Income |
52-Week High | $766.68 | $105.36 |
52-Week Low | $504.70 | $91.34 |
Typical Hold Time | 46 Days | 60 Days |
Enterprise Value | $41.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $518.00, up 2.24% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and product expansions highlight growth initiatives. Analyst consensus remains bullish with a $665 price target, though technical indicators suggest near-term caution.
Outlook remains positive driven by diagnostic innovation and recurring revenue growth, but faces headwinds from FX volatility and weaker U.S. vet visits. The 36.06 P/E ratio reflects premium valuation, requiring sustained execution. Risks include competitive pressures and insider selling, while institutional ownership trends show mixed signals.
TLH, an iShares 10-20 Year Treasury Bond ETF, trades at $92.19, up 0.81% on the day. The technical outlook is bearish based on moving averages, with neutral oscillators. Recent news highlights a challenging bond market environment, with Treasury yields reaching multi-decade highs, driving increased trading volume in the ETF. The fund continues its dividend distributions, with recent payments around $0.36-$0.38 per share.
The outlook for TLH is heavily influenced by the trajectory of long-term interest rates. Rising yields pressure bond prices, presenting headwinds, though the ETF offers income via dividends. Key risks include further Fed tightening and persistent inflation. Investors should weigh the income stability against potential capital depreciation in a rising rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About iShares 10 20 Year Treasury Bond ETF
TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.
Read more on TLH →
